Benitec Biopharma (NASDAQ:BNTC) Stock Rating Reaffirmed by JMP Securities

Benitec Biopharma (NASDAQ:BNTC)‘s stock had its “market outperform” rating reiterated by equities researchers at JMP Securities in a report issued on Monday, Benzinga reports. They presently have a $16.00 price target on the biotechnology company’s stock. JMP Securities’ price target points to a potential upside of 73.16% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Piper Sandler started coverage on Benitec Biopharma in a research report on Thursday, June 13th. They issued an “overweight” rating and a $30.00 price objective for the company. Leerink Partnrs upgraded shares of Benitec Biopharma to a “strong-buy” rating in a report on Monday, July 22nd. Leerink Partners started coverage on shares of Benitec Biopharma in a report on Monday, July 22nd. They issued an “outperform” rating and a $13.00 price target on the stock. Finally, Guggenheim started coverage on shares of Benitec Biopharma in a report on Thursday, September 12th. They set a “buy” rating and a $17.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $19.00.

Benitec Biopharma Trading Up 0.1 %

Shares of NASDAQ:BNTC traded up $0.01 on Monday, reaching $9.24. 228 shares of the company traded hands, compared to its average volume of 46,350. Benitec Biopharma has a 52 week low of $2.69 and a 52 week high of $10.88. The company has a quick ratio of 4.18, a current ratio of 4.18 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $8.85 and its 200 day simple moving average is $7.92.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its position in shares of Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after buying an additional 64,092 shares during the period. GAMMA Investing LLC grew its holdings in Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,884 shares during the period. Simplify Asset Management Inc. bought a new position in shares of Benitec Biopharma during the second quarter valued at approximately $358,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Benitec Biopharma in the 2nd quarter worth approximately $5,881,000. Institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.